Endocrine

, Volume 42, Issue 3, pp 506–513

Radioiodine treatment of well-differentiated thyroid cancer

Review

References

  1. 1.
    S.M. Seidin, L.D. Marinelli, E. Oshry, Radioactive iodine therapy effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132, 838–847 (1946)CrossRefGoogle Scholar
  2. 2.
    W.H. Beierwaltes, R. Rabbani, C. Dmuchowski et al., An analysis of ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J. Nucl. Med. 25, 1287–1293 (1984)PubMedGoogle Scholar
  3. 3.
    M. Schlumberger, C. Challeton, F. De Vathaire et al., Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37, 598–605 (1996)PubMedGoogle Scholar
  4. 4.
    T. Petrich, A. Widjaja, T.J. Musholt et al., Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur. J. Nucl. Med. 28, 203–208 (2001)PubMedCrossRefGoogle Scholar
  5. 5.
    A.P. Brown, W.P. Greening, V.R. McCready, H.J. Shaw, C.L. Harmer, Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br. J. Radiol. 57, 323–327 (1984)PubMedCrossRefGoogle Scholar
  6. 6.
    C. Menzel, F. Grunwald, A. Schomburg et al., “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J. Nucl. Med. 37, 1496–1503 (1996)PubMedGoogle Scholar
  7. 7.
    E. Hindié, D. Melliere, F. Lange et al., Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur. J. Nucl. Med. 30, 974–981 (2003)CrossRefGoogle Scholar
  8. 8.
    D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)PubMedCrossRefGoogle Scholar
  9. 9.
    F. Pacini, M. Schlumberger, H. Drale et al., European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006)PubMedCrossRefGoogle Scholar
  10. 10.
    F. Atkins, D. Van Nostrand, Radioiodine Whole Body Imaging, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, ed. by L. Wartofsky, Van Nostrand (Humana Press, Totowa, 2006), pp. 133–150Google Scholar
  11. 11.
    R. McDougal, in Differentiated Thyroid Cancer, ed. by R. McDougal. Management of Thyroid Cancer and Related Nodular Disease (Springer, New York, 2006), p. 173Google Scholar
  12. 12.
    D. Van Nostrand, M. Aiken, F. Atkins, S. Moreau, C. Garcia, E. Acio, K. Burman, L. Wartofsky, The utility of radioiodine scans prior to iodine-131 ablation in patients with well differentiated thyroid cancer. Thyroid 19, 849–855 (2009)PubMedCrossRefGoogle Scholar
  13. 13.
    M.-K. Chen, M. Yasrebi, J. Samii, L.H. Staib, I. Doddamane, D.W. Cheng, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid 22, 304–308 (2012)PubMedCrossRefGoogle Scholar
  14. 14.
    M.J. Schlumberger, F. Pacini, The low utility of pre-therapy scans in thyroid cancer patients. Thyroid 19, 815–816 (2009)PubMedCrossRefGoogle Scholar
  15. 15.
    D. Van Nostrand, F. Atkins, F. Yeganeh et al., Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12, 121–134 (2002)PubMedCrossRefGoogle Scholar
  16. 16.
    H.R. Maxon, S.R. Thomas, V.S. Hertzbert, J.G. Kereiakes, I.W. Chen, M.I. Sperling, E.L. Saenger, Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med. 309, 937–941 (1983)PubMedCrossRefGoogle Scholar
  17. 17.
    S.R. Thomas, H.R. Maxon, J.G. Kereiakes, In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys. 3, 253–255 (1976)CrossRefGoogle Scholar
  18. 18.
    R.S. Benua, N.R. Cicale, M. Sonenberg, R.W. Rawson, The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87, 171–182 (1962)Google Scholar
  19. 19.
    G. Sgouros, Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med. 34, 689–694 (1993)PubMedGoogle Scholar
  20. 20.
    R. Dorn, J. Kopp, H. Vogt et al., Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-based approach. J. Nucl. Med. 44, 451–456 (2003)PubMedGoogle Scholar
  21. 21.
    R. Leeper, Controversies in the treatment of thyroid cancer: the New York Memorial Hospital approach. Thyroid Today 5, 1–4 (1982)Google Scholar
  22. 22.
    K. Kulkarni, D. Van Nostrand, F.B. Atkins, M.J. Aiken, K. Burman, L. Wartofsky, The frequency with which empiric amounts of radioiodine “over-” or “under-” treat patients with metastatic well-differentiated thyroid cancer. Thyroid 16, 1019–1023 (2006)PubMedCrossRefGoogle Scholar
  23. 23.
    R.M. Tuttle, R. Leboeuf, R.J. Robbins et al., Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med. 47, 1587–1591 (2006)PubMedGoogle Scholar
  24. 24.
    J. Klubo-Gwiezdzinska, D. Van Nostrand, F. Atkins, K. Burman, J. Jonklaas, M. Mete, L. Wartofsky, Efficacy of dosimetric versus empiric prescribed activity of 131-I for therapy of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 3217–3225 (2011)PubMedCrossRefGoogle Scholar
  25. 25.
    D. Van Nostrand, Radioiodine Ablation, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edn., ed. by L. Wartofsky, D. Van Nostrand (Humana Press, Totowa, 2011), pp. 611–612Google Scholar
  26. 26.
    D. Van Nostrand, Radioiodine Treatment for Distant Metastases, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edn., ed. by L. Wartofsky, D. Van Nostrand (Humana Press, Totowa, 2006), pp. 611–612Google Scholar
  27. 27.
    M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet et al., Strategies of radioiodine ablation in patients with low risk thyroid cancer. N. Engl. J. Med. 366, 1663–1673 (2012)PubMedCrossRefGoogle Scholar
  28. 28.
    U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke, L. Moss, A. Nicol et al., Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012)PubMedCrossRefGoogle Scholar
  29. 29.
    C. Schvartz, F. Bonnetain, S. Dabakuyo, M. Gauthier, A. Cueff, S. Fieffe et al., Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J. Clin. Endocrinol. Metab. 97, 1526–1535 (2012)PubMedCrossRefGoogle Scholar
  30. 30.
    R.K. Alexander, P.R. Larsen, Radioiodine for thyroid cancer—is less more? New Engl. J. Med. 366, 1732–1733 (2012)PubMedCrossRefGoogle Scholar
  31. 31.
    L. Wartofsky, Management of papillary microcarcinoma: primum non nocere. J. Clin. Endocrinol. Metab. 97, 1169–1172 (2012)PubMedCrossRefGoogle Scholar
  32. 32.
    EANM, EANM procedure guidelines for therapy with iodine-131. Eur. J. Nucl. Med. 30, BP27–BP31 (2003)Google Scholar
  33. 33.
    J.C. Reynolds, in Comparison of I-131Absorbed Radiation Doses in Children and Adults; A Tool for Estimating Therapeutic I-131 Doses in Children. ed. by J. Robbins. Treatment of Thyroid Cancer in Children, (DOE/EH-0406, US Department of Commerce Technology Administration, National Technical Information Service, Springfield, 1994), pp. 127–135Google Scholar
  34. 34.
    M.D. Ringel, S.J. Burgun, in Recombinant Human Thyrotropin. ed. by L Wartofsky, D. Van Nostrand. Thyroid Cancer: A Comprehensive Guide to Clinical Management (Humana Press, Totowa, 2006), pp. 103–116Google Scholar
  35. 35.
    P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri et al., Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 337, 888–896 (1997)PubMedCrossRefGoogle Scholar
  36. 36.
    R.J. Robbins, R.M. Tuttle, M. Sonenberg, A. Shaha, R. Sharaf, H. Robbins, M. Fleisher, S.M. Larson, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11(9), 865–869 (2001)PubMedCrossRefGoogle Scholar
  37. 37.
    R. Elisei, M. Schlumberger, A. Driedger, C. Reiners, R.T. Kloos, S.I. Sherman et al., Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 294, 4171–4179 (2009)CrossRefGoogle Scholar
  38. 38.
    P.W. Rosario, A.F.M. Filho, R.X. Lacerda, M.R. Calsolari, Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid 222, 332–333 (2012)CrossRefGoogle Scholar
  39. 39.
    C. Durante, S. Filetti, Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. J. Clin. Endocrinol. Metab. 96, 3059–3061 (2011)PubMedCrossRefGoogle Scholar
  40. 40.
    R.J. Robbins, S.M. Larson, N. Sinha, A. Shaha, C. Divgi, K.S. Pentlow, R. Ghossein, R.M. Tuttle, A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J. Nucl. Med. 43(11), 1482–1488 (2002)PubMedGoogle Scholar
  41. 41.
    F. Pacini, E. Molinaro, M.G. Castagna, F. Lippi, C. Ceccarelli, L. Agate, R. Elisei, A. Pinchera, Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 87(9), 4063–4068 (2002)PubMedCrossRefGoogle Scholar
  42. 42.
    D. Barbaro, G. Boni, G. Meucci, G. Simi, P. Lapi, P. Orsini, C. Pasquini, F. Piazza, M. Caciagli, G. Mariani, Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J. Clin. Endocrinol. Metab. 88(9), 4110–4115 (2003)PubMedCrossRefGoogle Scholar
  43. 43.
    F. Pacini, P.W. Ladenson, M. Schlumberger et al., Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926–932 (2006)PubMedCrossRefGoogle Scholar
  44. 44.
    D. Van Nostrand, G.R. Khorjekar, J. O’Neil, S. Moreau, F.B. Atkins, P. Kharazi et al., Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131-I planar whole-body imaging and 124-I PET. J. Nucl. Med. 53, 359–362 (2012)PubMedCrossRefGoogle Scholar
  45. 45.
    J. Klubo-Gwiezdzinska, K.D. Burman, D. Van Nostrand, M. Mete, J. Jonklaas, L. Wartofsky, Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid 22, 310–317 (2012)PubMedCrossRefGoogle Scholar
  46. 46.
    H. Tala, R. Robbins, J.A. Fagin, S.M. Larson, R.M. Tuttle, Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J. Clin. Endocrinol. Metab. 96, 2105–2111 (2011)PubMedCrossRefGoogle Scholar
  47. 47.
    S.J. Bonnema, S. Fast, L. Hedgedusw, Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131-I therapy. Endocrine 40, 344–353 (2011)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Medicine, Washington Hospital CenterGeorgetown University Medical CenterWashingtonUSA
  2. 2.Nuclear Medicine, Washington Hospital CenterGeorgetown University Medical CenterWashingtonUSA

Personalised recommendations